NR4A3 and cancer: Our study not only identifies a novel posttranslational modulation of NR4A3 in VEC injury but also provides new clues related to SMARCB1 to explore the regulatory mechanism of pathophysiological processes involving NR4A receptors including metabolic disease, inflammation, cardiovascular disease, neurological functions, immune responses, and cancer.